King A G, Talmadge J E, Badger A M, Pelus L M
Department of Anti-Infectives, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406.
Exp Hematol. 1992 Feb;20(2):223-8.
It has been reported that the granulocyte-derived hematoregulatory pentapeptide, HP-5, and its dimer (HP-5b) have potent hematoregulatory properties. The proposed mechanism of action for HP-5b is synergy with colony-stimulating activity (CSA) resulting in enhanced myeloid colony formation in vitro. We now demonstrate that the effects of HP-5b on enhanced colony formation are indirect and mediated by an effect on CSA production by bone marrow stromal cells. Bone marrow stromal cell culture systems from mice, rats, and humans were used as target cells for the action of HP-5 monomer and dimer. Cell-free supernatants from these cultures were assayed for CSA in a murine granulocyte-macrophage colony-forming unit (CFU-GM) assay. Supernatants from stromal cell cultures pulsed for 1 h with HP-5b resulted in increased murine CFU-GM colony proliferation with an estimated half-maximal effective concentration (EC50) of 1-5 ng/ml. This increase in CFU-GM proliferation was neutralized by anti-macrophage colony-stimulating factor (anti-M-CSF) antibodies. The HP-5 monomer was without effect on constitutive CSA production by stromal cells, but it antagonized HP-5b-induced CSA production in a dose-responsive manner with an estimated half-maximal inhibitory concentration (IC50) of 0.2-0.4 ng/ml. The ability of HP-5 monomer to antagonize HP-5b induction of CSA appears specific in that HP-5 monomer failed to alter interleukin 1 (IL-1) or lipopolysaccharide (LPS)-induced stromal cell CSA production.
据报道,粒细胞源性血液调节五肽HP-5及其二聚体(HP-5b)具有强大的血液调节特性。HP-5b的作用机制被认为是与集落刺激活性(CSA)协同作用,从而在体外增强髓系集落形成。我们现在证明,HP-5b对增强集落形成的作用是间接的,并且是通过对骨髓基质细胞产生CSA的影响介导的。来自小鼠、大鼠和人类的骨髓基质细胞培养系统被用作HP-5单体和二聚体作用的靶细胞。这些培养物的无细胞上清液在小鼠粒细胞-巨噬细胞集落形成单位(CFU-GM)测定中检测CSA。用HP-5b脉冲处理1小时的基质细胞培养物的上清液导致小鼠CFU-GM集落增殖增加,估计半数最大有效浓度(EC50)为1-5 ng/ml。CFU-GM增殖的这种增加被抗巨噬细胞集落刺激因子(抗M-CSF)抗体中和。HP-5单体对基质细胞组成性CSA的产生没有影响,但它以剂量反应方式拮抗HP-5b诱导的CSA产生,估计半数最大抑制浓度(IC50)为0.2-0.4 ng/ml。HP-5单体拮抗HP-5b诱导CSA的能力似乎具有特异性,因为HP-5单体未能改变白细胞介素1(IL-1)或脂多糖(LPS)诱导的基质细胞CSA产生。